Bladder Cancer | Topics

Erdafitinib/Cetrelimab Combination Shows Strong Efficacy for Metastatic Urothelial Carcinoma
September 17, 2021

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

FDA Approves Adjuvant Nivolumab for the Treatment of Patients With High-Risk Urothelial Carcinoma
August 20, 2021

The FDA has approved nivolumab for patients with high-risk urothelial carcinoma regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status.

Adjuvant Nivolumab Demonstrates Improved Disease-Free Survival Over Placebo in Muscle Invasive Urothelial Carcinoma
July 29, 2021

Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with those who received placebo.